Tumor-Agnostic Approvals: Insights and Practical Considerations

Area of Science:

• Oncology
• Pharmacology
• Regulatory Science

Background:

• The FDA approved the first tumor-agnostic indication in 2017.
• Six drugs have received seven tumor-agnostic approvals to date.
• Tumor-agnostic therapies target specific molecular alterations irrespective of tumor origin.

Purpose of the Study:

• To provide a comprehensive summary of FDA-approved tumor-agnostic indications.
• To detail mechanisms of action, biomarker prevalence, study designs, and companion diagnostics.
• To discuss regulatory and health technology assessment aspects, including global comparisons.

Main Methods:

• Review of seven FDA-approved tumor-agnostic indications.
• Analysis of study designs, biomarker strategies, and regulatory submissions.
• Examination of health technology assessment and global regulatory landscapes.

Main Results:

• Summary of six drugs with seven tumor-agnostic approvals since 2017.
• Detailed review of mechanisms, biomarkers, study designs, and companion diagnostics.
• Comparative analysis of global regulatory requirements and HTA approvals.

Conclusions:

• Practical considerations for designing and developing tumor-agnostic therapies are presented.
• Recommendations are provided to mitigate risks during the design phase.
• Strategies for post-approval drug development, including confirmatory basket trials, are discussed.